CITN prioritizes our research by selecting novel agents with proven immunologic or physiologic function. We conduct small (early phase), novel studies of these high-priority agents in patients with cancer that would lead to larger phase trials, ultimately resulting in FDA approval.
Given our limited funding and the urgency of developing new cancer immunotherapies, CITN is strategic in our choice of agents selected for early phase testing. We prioritize agents that
CITN has initiated immunotherapy clinical trials across North America for patients with a variety of cancers:
CITN has pioneered clinical research protocols to include HIV-positive patients with cancer. In partnership with Dr. Thomas S. Uldrick, Deputy Head of Global Oncology at Fred Hutch, we are spearheading an international trial for these patients and have begun changing standards of care for this emerging population.
In 2017, CITN was awarded a grant to develop immunotherapy trials for children and teens with cancer at sites across North America. Under the direction of Dr. Crystal Mackall of Stanford University, the Pediatric CITN (PedCITN) includes:
PedCITN researchers specialize in a variety of childhood cancers including brain tumors, leukemia, hematology cancers, neuroblastoma, rare tumors, etc.
CITN relies on our membership of leading cancer immunologists to access the most promising immunotherapeutic agents known to date. We then collaborate with our industry and philanthropic partners to develop early-stage trials that provide the quickest route from proof of concept to patient benefit and regulatory approval.